Valuation: Autolus Therapeutics plc

Market Cap 51Cr 45Cr 42Cr 38Cr 72Cr 4.87TCr 72Cr 504.02Cr 194.91Cr 2.49TCr 190.86Cr 186.72Cr 7.99TCr P/E 2026 *
-2.3x
P/E 2027 * -2.72x
Enterprise Value 35Cr 31Cr 29Cr 27Cr 50Cr 3.38TCr 50Cr 349.33Cr 135.09Cr 1.72TCr 132.28Cr 129.41Cr 5.54TCr EV / Sales 2026 *
2.35x
EV / Sales 2027 * 2.24x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.88%
1 week-3.39%
Current month-21.06%
1 month-20.73%
3 months+16.67%
6 months+40.53%
Current year-6.78%
1 week 1.85
Extreme 1.85
2.08
1 month 1.84
Extreme 1.835
2.42
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Executive/Senior Manager

-6,713 0.0025%
29/06/26 Free

Director

79,167 0.0477%
18/03/26 Other

Chief Executive Officer

69,17,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-2.88%-3.39%+18.91%-20.73% 51Cr
-1.00%-0.18%+36.58%-4.46% 7.95TCr
+2.08%+25.82%+668.47%+98.90% 7.78TCr
-1.21%-0.34%-10.33%-29.82% 6.02TCr
-1.80%-2.15%-15.06%+26.38% 4.61TCr
+1.18%+2.78%+4.84%+161.08% 4.59TCr
+0.55%+3.90%+65.32%-11.67% 3.34TCr
-0.44%-2.92%+47.21%+113.24% 2.52TCr
-0.10%+3.69%+4.89%+166.22% 2.22TCr
+0.05%-2.15%+57.47%+98.45% 1.52TCr
Average -0.70%+2.63%+87.83%+59.76% 4.06TCr
Weighted average by Cap. -0.70%+4.92%+143.26%+53.68%

Financials

2026 *2027 *
Net sales 15Cr 13Cr 12Cr 11Cr 21Cr 1.43TCr 21Cr 148.5Cr 57Cr 732.68Cr 56Cr 55Cr 2.35TCr 19Cr 17Cr 16Cr 15Cr 27Cr 1.84TCr 27Cr 190.78Cr 74Cr 941.25Cr 72Cr 71Cr 3.02TCr
Net income -22Cr -19Cr -18Cr -17Cr -31Cr -2.1TCr -31Cr -216.97Cr -84Cr -1.07TCr -82Cr -80Cr -3.44TCr -19Cr -16Cr -15Cr -14Cr -26Cr -1.78TCr -26Cr -183.82Cr -71Cr -906.93Cr -70Cr -68Cr -2.91TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -22Cr -1.49TCr -22Cr -154.7Cr -60Cr -763.24Cr -59Cr -57Cr -2.45TCr -7.74Cr -6.79Cr -6.41Cr -5.84Cr -11Cr -741.3Cr -11Cr -77Cr -30Cr -378.5Cr -29Cr -28Cr -1.22TCr
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
25/26/25 $1.855 -2.88% 13,83,285
24/26/24 $1.910 -2.05% 18,19,211
23/26/23 $1.950 -3.94% 14,42,556
22/26/22 $2.030 +4.64% 15,69,963
21/26/21 $1.940 0.00% 11,01,473
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.855USD
Average target price
8.725USD
Spread / Average Target
+370.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock